Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B

Dore Gregory J.; Grebely Jason; Altice Frederick; Litwin Alain H.; Dalgard Olav; Gane Edward J.; Shibolet Oren; Conway Brian; Nahass Ronald; Luetkemeyer Anne; Peng Cheng-Yuan; Iser David M.; Gendrano Isaias N.; Kelly Michelle M.; Huang Hsueh-cheng; Hwang Peggy; Barr Eliav; Robertson Michael; Platt Heather

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B

【24h】

Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B

机译：丙型肝炎病毒（HCV）在阿片式激动剂治疗（OAT）中的ELBASVIR（EBR）/ Grazoprevir（GZR）治疗后的Elbasvir（EBR）/ Grazoprevir（GZR）治疗（燕麦）的治疗（燕麦）：共星部分B.

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2017年第1期|共2页
作者
Dore Gregory J.; Grebely Jason; Altice Frederick; Litwin Alain H.; Dalgard Olav; Gane Edward J.; Shibolet Oren; Conway Brian; Nahass Ronald; Luetkemeyer Anne; Peng Cheng-Yuan; Iser David M.; Gendrano Isaias N.; Kelly Michelle M.; Huang Hsueh-cheng; Hwang Peggy; Barr Eliav; Robertson Michael; Platt Heather;
展开▼
作者单位

UNSW Sydney Kirby Inst Sydney NSW Australia;

UNSW Sydney Kirby Inst Sydney NSW Australia;

Yale Univ New Haven CT USA;

Montefiore Med Ctr Albert Einstein Coll Med Bronx NY 10467 USA;

Akershus Univ Inst Clin Med Oslo Norway;

Auckland City Hosp Auckland New Zealand;

Tel Aviv Med Ctr &

Sch Med Dept Gastroenterol Liver Unit Tel Aviv Israel;

Vancouver Infect Dis Ctr Vancouver BC Canada;

ID Care Hillsborough NJ USA;

Univ Calif San Francisco San Francisco CA 94143 USA;

China Med Univ Hosp Taichung Taiwan;

St Vincents Univ Hosp Melbourne Vic Australia;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B [J] . Dore Gregory J., Grebely Jason, Altice Frederick, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：丙型肝炎病毒（HCV）在阿片式激动剂治疗（OAT）中的ELBASVIR（EBR）/ Grazoprevir（GZR）治疗后的Elbasvir（EBR）/ Grazoprevir（GZR）治疗（燕麦）的治疗（燕麦）：共星部分B.
2. Safety and Efficacy of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1-and GT4-infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials [J] . Flamm Steven L., Peng Cheng-Yuan, Shibolet Oren, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：Elbasvir（EBR）/ GrazoPrevir（GZR）在丙型肝炎病毒（HCV）的安全性和有效性（HCV）GT1-and GT4感染者65岁及以上的参与者：对12种临床试验的综合分析
3. P1‐085: Utilization and effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in treatment Na?ve (TN) genotype 1a (G1a) chronic hepatitis C virus (HCV) patients with/without baseline NS5A resistance‐associated substitutions (RASs) [J] . Journal of viral hepatitis. . 2018,第S1期

机译：P1-085：Elbasvir / Grazoprevir（EBR / GZR）治疗Naαve（TN）基因型1A（G1A）慢性丙型肝炎病毒（HCV）患者的利用和有效性，无基线NS5A抗性相关替代（RASS）
4. Association between Hepatitis C Virus knowledge and drug use risk behaviors among people who inject drugs, Ciudad Juarez, Chihuahua, 2012 [D] . Morgan, Leah Nicole. 2014

机译：注射毒品人群中丙型肝炎病毒知识与吸毒风险行为之间的关联，华雷斯城，奇瓦瓦州，2012年
5. A172 C-EDGE CO-STAR: RISK OF REINFECTION FOLLOWING SUCCESSFUL THERAPY WITH ELBASVIR (EBR) AND GRAZOPREVIR (GZR) IN PERSONS WHO INJECT DRUGS (PWID) RECEIVING OPIOD AGONIST THERAPY (OAT) [O] . B Conway, G J Dore, F Altice, 2018

机译：A172 C-EDGE联合明星：接受药物（PWID）感染的人（接受过类似的变性药物治疗）后接受ELBASVIR（EBR）和GRAZOPREVIR（GZR）成功治疗后有再感染风险
6. PUK14 Projected Clinical And Economic Impact Of Grazoprevir (Gzr, Mk-5172)/Elbasvir (Ebr, Mk-8742) For Chronic Hcv Genotype 1 Infection In Chronic Kidney Disease [O] . Elbasha EH, Ferrante S, Agarwal E, 2015

机译：PUK14预测的Grazoprevir（Gzr，Mk-5172）/ Elbasvir（Ebr，Mk-8742）对慢性Hcv基因1型慢性肾脏病感染的临床和经济影响

Hepatitis C Virus (HCV) Reinfection and Injecting Risk Behavior Following Elbasvir (EBR)/Grazoprevir (GZR) Treatment in Participants on Opiate Agonist Therapy (OAT): Co-STAR Part B

著录项

引文网络

相似文献

相关主题

期刊订阅